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MORE ACCURATE DETERMINATION OF BLOOD VOLUME ALLOWS FOR
A HIGH CORRELATION OF PRE-APHERESIS PERIPHERAL BLOOD AND FI-
NAL APHERESIS PRODUCT CD34+ CELL COUNTS
Parker, B.1, Hastings, J.2, Folkert, J.2, Nagy, G.2, Bachier, C.1,
LeMaistre, C.F.1, Shaughnessy, P.J.1 1Texas Transplant Institute, San
Antonio, TX; 2Methodist Hospital, San Antonio, TX
The final apheresis product CD34+ cell count is used to determine
if more apheresis procedures are necessary to collect sufficient hema-
topoietic stem cells for autologous (auto) peripheral blood stem cell
transplantation. Flow cytometric analysis of CD34+ cells can take
several hours. A more timely way to predict apheresis product
CD34+ cell counts may help determine if further cytokines are nec-
essary or if apheresis catheters can be removed, and improve the ef-
ficiency of patient (pt) care. We performed a retrospective review of
all pts undergoing auto peripheral blood (PB) stem cell mobilization
with G-CSF alone, G-CSF and plerixafor, or with chemotherapy
(chemo) followed by G-CSF, from July 2010 through May 2011
who underwent PB stem cell collection on the COBE Spectra cell
separator. Linear regression models were used to formulate pt blood
volume (BV) based on the pre-apheresis CD34+ cell count per micro
liter of blood, the final apheresis product CD34+ cell counts, and the
amount of blood processed during the apheresis procedure. This cal-
culated BV is expressed by the formula BV5 82.5(pts weight in Kg)
+ 793.We then prospectively evaluated the next consecutive pts who
underwent stem cell mobilization and apheresis in June and July
2011. Twenty-seven apheresis collections were done on 26 pts.
The PB CD34+ cell count/ul was multiplied by 1000 and this prod-
uct was multiplied by the calculated BV and then divided by the pts
weight [(PBCD34+ cell count x 1000) x BV]/Kg to determine the
predicted apheresis product CD34+ cell count, which was then com-
pared to the actual apheresis product final CD34+ cell count. On the
first day of collection the mean for the predicted product CD34+ cell
count was 4.98 x 106 +/- 3.1 x 106, and the actual apheresis product
CD34+ cell count was 4.61 x 106 +/- 2.90 x 106 (Pearson correlation r
value of 0.913 and a p value\0.001). There was no significant differ-
ence in the correlation between pts mobilized with G-CSF alone, G-
CSF and plerixafor or after chemo and G-CSF. In conclusion,
a more accurate determination of pt BV allowed for a high degree
of correlation on the first day of PB stem cell collection between
the predicted product CD34+ cell count and the actual apheresis
product CD34+ cell count. An accurate prediction of the final apher-
esis product CD34+ cell count may allow for less cytokine use,
quicker removal of catheters, and more efficient disposition of
patients.155
CXCL12 G801A POLYMORPHISMS DO NOT PREDICT RESPONSE TO
MOBILIZATION BY PLERIXAFOR IN NORMAL ALLOGENEIC STEM CELL
DONORS
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Several reports suggest that G/A transition at position
801(G801A) in the 3’ untranslated region (3’UTR) of CXCL12 in
donors mobilized with G-CSF can predict for response to mobiliza-
tion. It is unknown if this polymorphism impacts mobilization with
the CXCR4 antagonist plerixafor. We hypothesized that the AA
polymorphism would show increased stem cell mobilization in re-
sponse to plerixafor.
Methods: A cohort of 55 donors enrolled in a phase I/II clinical trial
evaluating IV plerixafor mobilization were evaluated. 21 donors inthe phase I portion were mobilized with IV plerixafor at increasing
doses (0.08, 0.16, 0.24, 0.32, 0.40, 0.48mg/kg) in a 3+3 design fol-
lowed by one week wash out then mobilization and apheresis collec-
tionwith 0.32mg/kg subcutaneous plerixafor. 34 donors in the phase
II portion of the trial were mobilized with 0.32mg/kg plerixafor IV.
The G801A polymorphism in the 3’UTR of the CXCL12 gene was
analyzed in peripheral bloodmononuclear cells isolated from phase I
and II donors. Final collected CD34/Kg recipient weight on day 1,
CD34/liter apheresis on day 1, and reaching goal collection of
.2x10e6CD34/kg recipient weight were used as the dependent vari-
ables in determining mean differences based on genotype and for
univariate analysis.
Results: A total of 55 allogeneic donors were mobilized (female/
male 5 25/30; age range 12 – 67 years, median 50 years). In total
54 were evaluable for genotyping. The frequency of genotypes in
the combined cohort of 54 individuals was: GG 5 38(69.1%), AG
5 14(25.5%), AA 5 2(3.6%). There was no detectable difference
in themean number of CD34 cells/L apheresis on day 1 of collection
by CXCL12 genotype (p5 0.78, ANOVA, CD34/liter log10 scale).
Mean CD34 cells/L apheresis (log10 scale) was: GG 5 7.021 (95%
CI 6.936, 7.107), AG 5 7.028 (95%CI 6.883, 7.172), AA 5 6.892
(95%CI 6.524, 7.260). The probability of collecting at least
2x10e6 CD34 cells/Kg recipient weight on day 1 was not affected
by CXCL12 genotype (logistic regression, p 5 0.74). The propor-
tion of patients with a successful collection on day 1 in each group
was: GG 5 64.86 (95%CI 47.46, 79.79), AG 5 53.85 (95%CI
25.13, 80.78), AA 5 50 (95% CI 1.26, 98.74).
Conclusion: These results suggest that unlike what has been re-
ported for normal allogeneic stem cell donors mobilized with G-
CSF, plerixafor mobilization yield is not affected by the CXCL12
3’UTR G801A polymorphism.156
RELATIONSHIPS AMONG COMMONLY USED MEASURES OF CORD BLOOD
POTENCY, ALDHBR CELL CONTENT, AND COLONY FORMING CELL CON-
TENT IN CORDBLOODUNITS PRIOR TO CRYOPRESERVATION: TOWARDS
AN IMPROVED METRIC FOR POTENCY OF BANKED CORD BLOOD
Page, K.1, Betz-Stablein, B.2, Mendizabal, A.2, Wease, S.2, Shoulars, K.1,
Gentry, T.1, Balber, A.E.3, Kurtzberg, J.1 1Duke University, Durham,
NC; 2The EMMES Corporation, Rockville, MD; 3Cicada Biopharma-
ceutical Consulting, Durham, NC
Despite adequate total nucleated cell (TNC) dosing, engraft-
ment delays and failures remain a significant issue for patients un-
dergoing cord blood (CB) transplantation. We have shown before
that post-thaw colony forming units (CFU) better predicted en-
graftment compared to TNC and CD34+. However, the CFU as-
say is not standardized and results take weeks. Aldehyde
dehydrogenase (ALDH), an enzyme expressed in stem and pro-
genitor cells (ALDHbr cells), is detected by a rapid functional,
flow-based intracellular assay. In this study, we explored statistical
relationships among TNC, mononuclear cell count (MNC),
CD34+, ALDHbr cells and CFU in a large cohort of fresh CB
units (CBU) prior to cryopreservation. Our ultimate goal is to
identify the best parameter(s) to predict potency as defined by suc-
cessful engraftment.
Methods: Post-processed TNC, MNC, CD34+ and CFU content
were routinely enumerated on fresh CBUs donated to the Carolinas
Cord Blood Bank for public (n5 5268) or directed use (n5 14) from
9/07-7/09. Aldecount (Aldagen, Inc) was used to measure
ALDHbr content. Statistical relationships were established.
Results: The median TNC, CD34+, MNC, ALDHbr and CFU
content were: 11.8x108(range, 2.9-55.5x108), 3.36 x106(range,
0.17-98.2x106), 5.5x108(range, 1.7-20.0x108), 4.3x 106(0-36.6x106)
and 34.0x105(range, 0.6-193.3x105), respectively. Significant corre-
lations existed among measured parameters (Table 1). By stan-
dardizing univariate models, we were able to rank using AIC values.
CFUwas best predicted byTNC (AIC5 11,501) followed closely by
ALDHbr (AIC 5 12,012) and, to a lesser degree, MNC (AIC 5
12,412) and CD34+ (AIC 5 12,612). Multivariate results were
similar (data not shown). Ratios of ALDHbr and CD34+ to CFU
were 1.36:1 and 1.09:1, respectively, whereas the ratio of TNC to
CFU was 332:1.
